Piper Sandler raises Abivax stock price target to $70 on positive UC trial data

Published 23/07/2025, 17:16
Piper Sandler raises Abivax stock price target to $70 on positive UC trial data

Investing.com - Piper Sandler raised its price target on Abivax (NASDAQ:ABVX) to $70.00 from $42.00 on Wednesday, while maintaining an Overweight rating following positive clinical trial results. According to InvestingPro data, analyst targets for ABVX range from $12 to $95, with the stock currently trading near its 52-week high after posting strong returns over the past three months.

The upgrade comes after Abivax disclosed topline induction data from its Phase 3 ABTECT program evaluating obefazimod in ulcerative colitis (UC) patients. The 50mg dose demonstrated a pooled 16.4% placebo-adjusted remission rate across both ABTECT studies at week 8, with high statistical significance (p

All key secondary endpoints in the trials also achieved statistical significance, according to the research note. The safety and tolerability profile of obefazimod was described as "very clean" in the analyst commentary.

Piper Sandler indicated that these results validate obefazimod’s "highly-differentiated profile" in the treatment of ulcerative colitis, leading to increased revenue estimates and the higher price target.

Maintenance data from the UC trials is expected in the second quarter of 2026, with regulatory filing to follow thereafter.

In other recent news, Abivax has announced positive results from its Phase 3 clinical trials for its ulcerative colitis treatment, obefazimod. The trials, known as ABTECT-1 and ABTECT-2, achieved primary endpoints, showing statistically significant clinical remission at Week 8 for the 50 mg dose. This promising data has led several financial firms to adjust their outlook on Abivax. Morgan Stanley (NYSE:MS) upgraded the company’s stock to Overweight, significantly raising its price target from $12.00 to $71.00. Similarly, Leerink Partners increased its price target from $20.00 to $74.00, maintaining an Outperform rating. Guggenheim also raised its price target to $101.00 from $50.00, while JMP Securities increased its target to $95.00 from $33.00, both maintaining favorable ratings. These developments highlight the strong market confidence in Abivax’s ulcerative colitis treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.